The Supreme Court declined to hear Teva's challenge to a $235 million award to GlaxoSmithKline in a patent dispute over generic drugs involving heart medication Coreg, according to a Reuters report.

As promised back in February, Teva Pharmaceuticals has asked the U.S. Supreme Court to overturn its $235 million loss in the company’s long-running “skinny label” patent feud with GSK. The case, which ...

The use of low-dose carvedilol did not significantly improve certain cardiac measures of heart failure risk in long-term survivors of childhood cancer exposed to anthracycline compared with placebo, ...

As of May 2026, the pharmacy landscape is defined by a paradox: Carvedilol is absent from official shortage lists, yet patients are reporting significant access issues due to fragmented generic supply ...

Maximum plasma concentrations of carvedilol occur 1-2 hours after oral administration. [9] Absolute bioavailability of carvedilol is approximately 23% due to extensive first-pass metabolism. [9] Food ...

A new court ruling has the future use of skinny labels in question, but skinny-label generics have saved Medicare a lot of money over 5 years. Skinny labels, which carve out patent-protected ...